Exchange: NASDAQ·Updated 07:18 AM EDT
DNLI logo

DNLI Denali Therapeutics Inc

$20.10
$0.10
(0.50%)
Pre-Market
Prev Close $20.00
EarningsNov 5
Mkt Cap$3.2B
Vol500.00

About DNLI

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
56

Bullish Sentiment

How do you feel about DNLI?

Advertisement|Remove ads.